News

The additions to the ANTERION Cornea App will be commercially available in February 2025

ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.

ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.

The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for the treatment of diabetic macular edema in October 2024.

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding that you may have missed.

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, and a dedicated webpage.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis

The collaboration between KIST and Huons BioPharma will span 14 months.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer.

Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer

Most recently, Jacques served as Vice President of Healthcare Strategy, Partnerships & M&A at Microsoft.

The multinational, multicenter, prospective RESTORE Study is the 5-year follow-up study of the phase 3 clinical RESCUE and REVERSE Studies of lenadogene nolparvovec to treat vision loss from LHON due to the MT-ND4 mutation.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

LHON, a genetic disease that affects the retinal ganglion cells, results in severe bilateral sequential vision loss.

The RESTORE Study is the follow-up study of the RESCUE and REVERSE studies of lenadogene nolparvovec to treat vision loss from LHON

The potential gene therapy candidate is being evaluated for geographic atrophy.

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition.

Lana Rifkin, MD, a uveitis specialist at Ophthalmic Consultants of Boston, shared insights into her work and her role as committee chair of the uveitis section for the upcoming EnVision Summit, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.